Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metastasizing ameloblastoma.

E H Laughlin1

  • 1School of Primary Care, University of Alabama, Huntsville.

Cancer
|August 1, 1989
PubMed
Summary
This summary is machine-generated.

Metastatic ameloblastoma is rare, with a median 9-year disease-free interval before metastasis and 2-year survival after. Early primary tumor resection is crucial to prevent spread.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Minimal-access surgery for staging of malignant melanoma.

Archives of surgery (Chicago, Ill. : 1960)·1995
Same author

Benign and malignant neoplasms in a family with Peutz-Jeghers syndrome: study of three generations.

Southern medical journal·1991
Same author

Treatment of early-stage breast cancer. Many questions, a few answers.

Alabama medicine : journal of the Medical Association of the State of Alabama·1991
Same author

Have changing treatment patterns affected outcome for operable breast cancer? Ten-year follow-up in 1288 patients, 1965 to 1978.

Annals of surgery·1991
Same author

Palliating late-stage esophageal cancer.

Alabama medicine : journal of the Medical Association of the State of Alabama·1989
Same author

Common duct stricture associated with hepatic artery infusion of FUDR.

Journal of surgical oncology·1986
Same journal

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

Cancer·2026
Same journal

Bendamustine in indolent lymphoma: Letting the dust settle down.

Cancer·2026
Same journal

Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma.

Cancer·2026
Same journal

Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality.

Cancer·2026
Same journal

Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States.

Cancer·2026
Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026
See all related articles

Area of Science:

  • Oncology
  • Oral Pathology

Background:

  • Ameloblastoma is a rare odontogenic tumor.
  • Metastatic potential is uncommon but significant.

Observation:

  • A case of malignant ameloblastoma with indolent metastases is presented.
  • A review of 42 published cases of metastasizing ameloblastoma was conducted.
  • Most metastases occurred in the lung.

Findings:

  • The median disease-free interval (DFI) to metastasis was 9 years in 43 patients.
  • The median survival time post-metastasis was 2 years.
  • Metastasis appears linked to multiple tumor recurrences.

Implications:

  • Early and adequate primary tumor resection is recommended to prevent metastasis.
  • Surgical excision is the preferred treatment for metastases.
  • Radiation therapy may be considered for unresectable lesions.
  • Chemotherapy shows no apparent efficacy in disseminated ameloblastoma.